BioCryst Names David W. Jenkins Chief Scientific Officer To Drive Rare Disease Pipeline

BioCryst Pharmaceuticals appointed David W. Jenkins, MA, PhD, as Chief Scientific Officer (new role) effective immediately, reporting to C R&D head Dr. Sandeep Menon. No financial guidance, trial readouts, or other material business updates were cited, suggesting limited near-term impact.

Analysis

BioCryst Pharmaceuticals appointed David W. Jenkins, MA, PhD, as Chief Scientific Officer (new role) effective immediately, reporting to C R&D head Dr. Sandeep Menon. No financial guidance, trial readouts, or other material business updates were cited, suggesting limited near-term impact.